SpringWorks Therapeutics, Inc., a Stamford, Conn.-based clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, closed a $125m Series B financing.
The round was led by Perceptive Advisors, with participation from new investors Boxer Capital of Tavistock Group, HBM Healthcare Investments, BVF Partners, Surveyor Capital (a Citadel company), Samsara BioCapital, ArrowMark Partners, GlaxoSmithKline (NYSE: GSK), and Laurion Capital Management, as well as existing investors OrbiMed, Bain Capital, Pfizer (NYSE: PFE), via Pfizer Ventures, and LifeArc.
The company intends to use the funds to advance its two late-stage rare disease oncology programs towards potential regulatory approval and commercialization and expand its emerging targeted oncology programs, as well as future in-licensing opportunities and clinical collaborations in rare diseases and cancer.
Led by Saqib Islam, Chief Executive Officer, SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that aims to identify and advance promising science, beginning with licensed clinical therapies from Pfizer Inc. Two of its therapies will be entering potentially pivotal studies in the first half of 2019:
– nirogacestat, a gamma secretase inhibitor for the treatment of desmoid tumors, and
– PD-0325901, a MEK 1/2 inhibitor for neurofibromatosis type 1 patients with plexiform neurofibromas.